• WST-8 Assays for Smart Hydrogel Research

  2026-10-01

  WST-8 assays provide a practical way to evaluate cell metabolic activity during smart hydrogel development. This guide explains how to interpret colorimetric viability data when antioxidant, antibacterial, and dynamically responsive materials may influence assay chemistry.

• Pseudo-UTP: Translating mRNA Design into Impact

  2026-10-01

  Pseudo-modified uridine triphosphate is more than a reagent substitution: it is a design lever for improving RNA persistence, translation, and tolerability in research workflows. This thought-leadership analysis connects Pseudo-UTP to findings from an Omicron KP.3 mRNA vaccine study and outlines how translational teams can move from promising animal data to better-controlled RNA development decisions.

• Deracoxib: COX-2 Inhibition in Canine Research

  2026-09-30

  Deracoxib is a selective COX-2 inhibitor used in veterinary pain, inflammation, and cancer biology research. Product data describe concentration-dependent activity in canine cell models, oral in vivo dosing benchmarks, and formulation constraints that should guide assay design rather than substitute for model-specific validation.

• Vancomycin Hydrochloride in Resistance Workflows

  2026-09-29

  Build more interpretable Gram-positive susceptibility, resistance, and infection-model workflows with a mechanistically defined comparator. This guide connects practical stock preparation and assay controls with emerging antimicrobial-peptide research, while separating evidence-backed parameters from pilot conditions that require local optimization.

• β-NMN Workflows for Metabolic Research

  2026-09-29

  Build reproducible NAD+ manipulation experiments with beta-Nicotinamide mononucleotide (β-NMN), from islet secretion assays to diabetic cardiac-remodeling models. This practical guide separates reported findings from suggested starting conditions and emphasizes formulation, controls, and mechanism-aware troubleshooting.

• MCL-1 Inhibition: From Mechanism to Translation

  2026-09-28

  MCL-1 inhibitor A-1210477 offers a selective way to test how cancer cells evade mitochondrial apoptosis. This thought-leadership guide connects MCL-1 biology, BAX/BAK-informed validation, combination strategy, experimental handling, and translational decision-making while defining the compound’s limits as an in vitro research tool.

• Bacitracin (B1670): Practical Research Guide

  2026-09-28

  Bacitracin (B1670) is a peptide antibiotic for controlled laboratory studies of bacterial growth and cell-wall or peptidoglycan synthesis disruption. Use it to investigate antibacterial effects under locally validated assay conditions; it is not intended for diagnostic, clinical, or medical use.

• Bufalin in HCC: Assay Workflow and Mechanistic Insight

  2026-09-27

  Use Bufalin to test how CENPA-associated glycolysis and PI3K/AKT signaling relate to hepatocellular carcinoma cell migration—not simply to measure viability. This guide turns recent HCC findings into a staged workflow with practical controls, optimization steps, and clear boundaries between reported evidence and suggested pilot conditions.

• Griseofulvin: A Workflow for Microtubule Assays

  2026-09-26

  Use Griseofulvin to investigate how microtubule disruption affects fungal growth, then adapt a carefully controlled mechanistic workflow to ask whether a cellular response is consistent with aneugenicity. This guide separates established reference-assay findings from practical starting conditions that researchers should optimize for their own model.

• Verapamil and the Timing of Urothelial Inflammation

  2026-09-25

  Verapamil ((±)-Verapamil) helps probe how hypoxia duration relates to urothelial inflammatory signaling. This article focuses on experimental interpretation: separating an early hypoxic response from later caspase-1 activation and recognizing what a pharmacological intervention can—and cannot—establish.

• Neuromedin S (rat): Assay and Handling Guide

  2026-09-25

  Neuromedin S (rat) provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein responses. Use it in research assays with suitable vehicle and receptor controls; it is not intended for diagnosis, treatment, or clinical use.

• Deferasirox in Nutrient-Stress and Lysosome Research

  2026-09-24

  Deferasirox is an oral iron chelator that can help researchers probe how iron availability intersects with nutrient stress and cell death. This article connects its iron-binding properties to recent TCF25–lysosome findings while clarifying what the experiments do—and do not—establish.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-09-24

  A 2024 study reports that reduced PPP2R2A expression increases replication stress and makes high-grade serous ovarian cancer (HGSOC) cells more vulnerable to CHK1 inhibition. The findings support PPP2R2A/PP2A B55α as a candidate response biomarker, including in PARP inhibitor-resistant models, but remain preclinical and require clinical validation.

• Vancomycin Hydrochloride: From Mechanism to Models

  2026-09-23

  A translational perspective on using vancomycin hydrochloride as a mechanistic benchmark—from D-Ala-D-Ala target engagement and susceptibility assays to infection-model design and comparison with antimicrobial peptides.

• Bobcat339: TET Inhibitor Workflow for Epigenetics

  2026-09-23

  Bobcat339 provides a practical pharmacological route to test whether TET1/2-dependent DNA demethylation contributes to gene regulation, stem-cell behavior, and osteogenic failure. This guide combines dose-finding, methylation and chromatin readouts, multi-omics integration, and troubleshooting for disease-relevant epigenetics workflows.

8126 records 1/542 page Next 12345 下5页 Last page